Session Chair Profile
M.D., Ph.D., Associate Professor of Laboratory Medicine and Medicine, Division of Infectious Diseases, UCSF; Director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC); Associate Director of the UCSF Clinical Microbiology Laboratory
Biography
Dr. Chiu’s laboratory is focused on clinical diagnostic next-generation sequencing assay development for infectious diseases using emerging technologies (nanopore sequencing, RNA-Seq host profiling), as well as investigation of emerging pathogens (Borrelia burgdorferi, Ebola virus, enterovirus D68, and Zika virus). He is the developer of the SURPI computational pipeline for pathogen identification from metagenomic data, and heads the “Precision Diagnosis of Acute Infectious Diseases” (PDAID) study, sponsored by the California Initiative to Advance Precision Medicine (CIAPM). His laboratory also develops new approaches for infectious disease diagnosis, including nanopore sequencing and RNA-Seq host response profiling. His work is also supported by research grants from the NIH, Bay Area Lyme Disease Foundation, UC Center for Accelerated Innovation, the Charles and Helen Schwab Foundation, the Gates Foundation, bioMérieux Inc., the USAID PREDICT program, and Abbott Laboratories, Inc. Dr. Chiu has authored more than 60 peer-reviewed publications, holds over 15 patents and patent applications, and serves on the scientific advisory board for Therabio, Inc. and Rubicon Genomics.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: This session will cover the development and validation of clinical next-generation sequencing (NGS) assays for infectious disease diagnosis in precision medicine and highlight the promise, pitfalls, and regulatory / reimbursement issues associated with these emerging tests.
